nodes	percent_of_prediction	percent_of_DWPC	metapath
Icosapent ethyl—DGAT1—Glycerophospholipid biosynthesis—EPT1—liver cancer	0.0469	0.135	CbGpPWpGaD
Icosapent ethyl—DGAT1—Vitamin A and Carotenoid Metabolism—CRABP1—liver cancer	0.0395	0.114	CbGpPWpGaD
Icosapent ethyl—DGAT1—Phospholipid metabolism—EPT1—liver cancer	0.0327	0.0944	CbGpPWpGaD
Icosapent ethyl—DGAT1—Vitamin A and Carotenoid Metabolism—CYP2E1—liver cancer	0.0281	0.0812	CbGpPWpGaD
Icosapent ethyl—Suicide—Sorafenib—liver cancer	0.019	0.0296	CcSEcCtD
Icosapent ethyl—DGAT1—Fatty acid, triacylglycerol, and ketone body metabolism—CPT1B—liver cancer	0.017	0.0492	CbGpPWpGaD
Icosapent ethyl—Completed suicide—Sorafenib—liver cancer	0.0167	0.0261	CcSEcCtD
Icosapent ethyl—DGAT1—Fatty acid, triacylglycerol, and ketone body metabolism—NR1H4—liver cancer	0.0164	0.0474	CbGpPWpGaD
Icosapent ethyl—DGAT1—Fatty acid, triacylglycerol, and ketone body metabolism—CRABP1—liver cancer	0.0126	0.0362	CbGpPWpGaD
Icosapent ethyl—Myocardial ischaemia—Sorafenib—liver cancer	0.0123	0.0191	CcSEcCtD
Icosapent ethyl—Icosapent—PPARG—liver cancer	0.0122	1	CrCbGaD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.0105	0.0304	CbGpPWpGaD
Icosapent ethyl—Rectal tenesmus—Epirubicin—liver cancer	0.00977	0.0152	CcSEcCtD
Icosapent ethyl—Rectal tenesmus—Doxorubicin—liver cancer	0.00904	0.0141	CcSEcCtD
Icosapent ethyl—Neoplasm—Sorafenib—liver cancer	0.0089	0.0139	CcSEcCtD
Icosapent ethyl—Eczema—Sorafenib—liver cancer	0.00796	0.0124	CcSEcCtD
Icosapent ethyl—Proctalgia—Epirubicin—liver cancer	0.00776	0.0121	CcSEcCtD
Icosapent ethyl—Peripheral vascular disorder—Epirubicin—liver cancer	0.00742	0.0116	CcSEcCtD
Icosapent ethyl—Proctalgia—Doxorubicin—liver cancer	0.00718	0.0112	CcSEcCtD
Icosapent ethyl—Peripheral vascular disorder—Doxorubicin—liver cancer	0.00687	0.0107	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.00678	0.0196	CbGpPWpGaD
Icosapent ethyl—Mood swings—Sorafenib—liver cancer	0.00677	0.0106	CcSEcCtD
Icosapent ethyl—Anorectal discomfort—Epirubicin—liver cancer	0.00666	0.0104	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.00654	0.0189	CbGpPWpGaD
Icosapent ethyl—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00644	0.01	CcSEcCtD
Icosapent ethyl—DGAT1—Fatty acid, triacylglycerol, and ketone body metabolism—CYP1A1—liver cancer	0.00643	0.0186	CbGpPWpGaD
Icosapent ethyl—Gastritis—Sorafenib—liver cancer	0.00633	0.00987	CcSEcCtD
Icosapent ethyl—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00631	0.00983	CcSEcCtD
Icosapent ethyl—DGAT1—Phospholipid metabolism—PIK3CG—liver cancer	0.00623	0.018	CbGpPWpGaD
Icosapent ethyl—Dysphagia—Sorafenib—liver cancer	0.00618	0.00963	CcSEcCtD
Icosapent ethyl—Anorectal discomfort—Doxorubicin—liver cancer	0.00616	0.00961	CcSEcCtD
Icosapent ethyl—Generalised oedema—Epirubicin—liver cancer	0.00612	0.00954	CcSEcCtD
Icosapent ethyl—Pancreatitis—Sorafenib—liver cancer	0.00606	0.00945	CcSEcCtD
Icosapent ethyl—Enlargement abdomen—Epirubicin—liver cancer	0.00605	0.00943	CcSEcCtD
Icosapent ethyl—Polyp—Epirubicin—liver cancer	0.00598	0.00933	CcSEcCtD
Icosapent ethyl—DGAT1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARA—liver cancer	0.00588	0.017	CbGpPWpGaD
Icosapent ethyl—Erectile dysfunction—Sorafenib—liver cancer	0.00569	0.00887	CcSEcCtD
Icosapent ethyl—Generalised oedema—Doxorubicin—liver cancer	0.00566	0.00883	CcSEcCtD
Icosapent ethyl—Enlargement abdomen—Doxorubicin—liver cancer	0.0056	0.00873	CcSEcCtD
Icosapent ethyl—Pneumonia—Sorafenib—liver cancer	0.00554	0.00864	CcSEcCtD
Icosapent ethyl—Polyp—Doxorubicin—liver cancer	0.00554	0.00863	CcSEcCtD
Icosapent ethyl—Infestation NOS—Sorafenib—liver cancer	0.00551	0.00859	CcSEcCtD
Icosapent ethyl—Infestation—Sorafenib—liver cancer	0.00551	0.00859	CcSEcCtD
Icosapent ethyl—DGAT1—Phospholipid metabolism—PIK3CD—liver cancer	0.00548	0.0158	CbGpPWpGaD
Icosapent ethyl—Cyst—Epirubicin—liver cancer	0.00544	0.00849	CcSEcCtD
Icosapent ethyl—Acute coronary syndrome—Sorafenib—liver cancer	0.00543	0.00847	CcSEcCtD
Icosapent ethyl—Myocardial infarction—Sorafenib—liver cancer	0.0054	0.00842	CcSEcCtD
Icosapent ethyl—Epistaxis—Sorafenib—liver cancer	0.0052	0.0081	CcSEcCtD
Icosapent ethyl—Hyperlipidaemia—Epirubicin—liver cancer	0.00505	0.00787	CcSEcCtD
Icosapent ethyl—Laryngitis—Epirubicin—liver cancer	0.00505	0.00787	CcSEcCtD
Icosapent ethyl—Cyst—Doxorubicin—liver cancer	0.00504	0.00786	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.005	0.0144	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism—UGDH—liver cancer	0.00499	0.0144	CbGpPWpGaD
Icosapent ethyl—DGAT1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—liver cancer	0.00486	0.014	CbGpPWpGaD
Icosapent ethyl—DGAT1—Phospholipid metabolism—PIK3CB—liver cancer	0.00477	0.0138	CbGpPWpGaD
Icosapent ethyl—Fungal infection—Epirubicin—liver cancer	0.00471	0.00735	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—EPT1—liver cancer	0.00469	0.0135	CbGpPWpGaD
Icosapent ethyl—Laryngitis—Doxorubicin—liver cancer	0.00467	0.00729	CcSEcCtD
Icosapent ethyl—Hyperlipidaemia—Doxorubicin—liver cancer	0.00467	0.00729	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—TAT—liver cancer	0.00444	0.0128	CbGpPWpGaD
Icosapent ethyl—Arrhythmia—Sorafenib—liver cancer	0.00442	0.00689	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.00437	0.0126	CbGpPWpGaD
Icosapent ethyl—Alopecia—Sorafenib—liver cancer	0.00437	0.00681	CcSEcCtD
Icosapent ethyl—Fungal infection—Doxorubicin—liver cancer	0.00436	0.0068	CcSEcCtD
Icosapent ethyl—Malnutrition—Sorafenib—liver cancer	0.00431	0.00671	CcSEcCtD
Icosapent ethyl—Dysgeusia—Sorafenib—liver cancer	0.00422	0.00657	CcSEcCtD
Icosapent ethyl—Viral infection—Epirubicin—liver cancer	0.00403	0.00628	CcSEcCtD
Icosapent ethyl—Cough increased—Epirubicin—liver cancer	0.00398	0.0062	CcSEcCtD
Icosapent ethyl—Syncope—Sorafenib—liver cancer	0.00386	0.00602	CcSEcCtD
Icosapent ethyl—Loss of consciousness—Sorafenib—liver cancer	0.00378	0.0059	CcSEcCtD
Icosapent ethyl—Cough—Sorafenib—liver cancer	0.00376	0.00586	CcSEcCtD
Icosapent ethyl—Viral infection—Doxorubicin—liver cancer	0.00373	0.00581	CcSEcCtD
Icosapent ethyl—Hypertension—Sorafenib—liver cancer	0.00372	0.0058	CcSEcCtD
Icosapent ethyl—Neck pain—Epirubicin—liver cancer	0.00368	0.00574	CcSEcCtD
Icosapent ethyl—Cough increased—Doxorubicin—liver cancer	0.00368	0.00574	CcSEcCtD
Icosapent ethyl—Arthralgia—Sorafenib—liver cancer	0.00367	0.00572	CcSEcCtD
Icosapent ethyl—Myalgia—Sorafenib—liver cancer	0.00367	0.00572	CcSEcCtD
Icosapent ethyl—Dry mouth—Sorafenib—liver cancer	0.00358	0.00559	CcSEcCtD
Icosapent ethyl—Eructation—Epirubicin—liver cancer	0.00358	0.00558	CcSEcCtD
Icosapent ethyl—Melaena—Epirubicin—liver cancer	0.00356	0.00554	CcSEcCtD
Icosapent ethyl—Anaphylactic shock—Sorafenib—liver cancer	0.00351	0.00548	CcSEcCtD
Icosapent ethyl—Colitis—Epirubicin—liver cancer	0.00349	0.00545	CcSEcCtD
Icosapent ethyl—Infection—Sorafenib—liver cancer	0.00349	0.00544	CcSEcCtD
Icosapent ethyl—Shock—Sorafenib—liver cancer	0.00346	0.00539	CcSEcCtD
Icosapent ethyl—Fluid retention—Epirubicin—liver cancer	0.00346	0.00539	CcSEcCtD
Icosapent ethyl—Neck pain—Doxorubicin—liver cancer	0.00341	0.00532	CcSEcCtD
Icosapent ethyl—Anorexia—Sorafenib—liver cancer	0.00335	0.00522	CcSEcCtD
Icosapent ethyl—Eructation—Doxorubicin—liver cancer	0.00331	0.00516	CcSEcCtD
Icosapent ethyl—Neoplasm—Epirubicin—liver cancer	0.00329	0.00513	CcSEcCtD
Icosapent ethyl—Melaena—Doxorubicin—liver cancer	0.00329	0.00513	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.00327	0.00944	CbGpPWpGaD
Icosapent ethyl—Colitis—Doxorubicin—liver cancer	0.00323	0.00504	CcSEcCtD
Icosapent ethyl—Musculoskeletal discomfort—Sorafenib—liver cancer	0.0032	0.00499	CcSEcCtD
Icosapent ethyl—Fluid retention—Doxorubicin—liver cancer	0.0032	0.00499	CcSEcCtD
Icosapent ethyl—Dyspnoea—Sorafenib—liver cancer	0.00313	0.00488	CcSEcCtD
Icosapent ethyl—Lymphadenopathy—Epirubicin—liver cancer	0.0031	0.00483	CcSEcCtD
Icosapent ethyl—Dyspepsia—Sorafenib—liver cancer	0.00309	0.00482	CcSEcCtD
Icosapent ethyl—Decreased appetite—Sorafenib—liver cancer	0.00305	0.00476	CcSEcCtD
Icosapent ethyl—Neoplasm—Doxorubicin—liver cancer	0.00304	0.00475	CcSEcCtD
Icosapent ethyl—Gastrointestinal disorder—Sorafenib—liver cancer	0.00303	0.00473	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—GLUL—liver cancer	0.00302	0.00872	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism—CPT1B—liver cancer	0.00302	0.00872	CbGpPWpGaD
Icosapent ethyl—Pain—Sorafenib—liver cancer	0.003	0.00469	CcSEcCtD
Icosapent ethyl—Constipation—Sorafenib—liver cancer	0.003	0.00469	CcSEcCtD
Icosapent ethyl—Eczema—Epirubicin—liver cancer	0.00294	0.00458	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—NR1H4—liver cancer	0.00291	0.00841	CbGpPWpGaD
Icosapent ethyl—DGAT1—Phospholipid metabolism—PIK3CA—liver cancer	0.00291	0.0084	CbGpPWpGaD
Icosapent ethyl—Lymphadenopathy—Doxorubicin—liver cancer	0.00287	0.00447	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—GSTA3—liver cancer	0.00286	0.00827	CbGpPWpGaD
Icosapent ethyl—Increased appetite—Epirubicin—liver cancer	0.00281	0.00439	CcSEcCtD
Icosapent ethyl—Body temperature increased—Sorafenib—liver cancer	0.00278	0.00433	CcSEcCtD
Icosapent ethyl—Eczema—Doxorubicin—liver cancer	0.00272	0.00424	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—GSTA4—liver cancer	0.00262	0.00756	CbGpPWpGaD
Icosapent ethyl—Increased appetite—Doxorubicin—liver cancer	0.0026	0.00406	CcSEcCtD
Icosapent ethyl—Affect lability—Epirubicin—liver cancer	0.0026	0.00406	CcSEcCtD
Icosapent ethyl—Migraine—Epirubicin—liver cancer	0.0026	0.00406	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.00256	0.00739	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism—GSTA2—liver cancer	0.00255	0.00737	CbGpPWpGaD
Icosapent ethyl—Asthenia—Sorafenib—liver cancer	0.00252	0.00393	CcSEcCtD
Icosapent ethyl—Cardiac arrest—Epirubicin—liver cancer	0.00251	0.00392	CcSEcCtD
Icosapent ethyl—Mood swings—Epirubicin—liver cancer	0.0025	0.0039	CcSEcCtD
Icosapent ethyl—Pruritus—Sorafenib—liver cancer	0.00249	0.00388	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—GSTA1—liver cancer	0.00246	0.00711	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism—NAT2—liver cancer	0.00244	0.00703	CbGpPWpGaD
Icosapent ethyl—Affect lability—Doxorubicin—liver cancer	0.00241	0.00375	CcSEcCtD
Icosapent ethyl—Migraine—Doxorubicin—liver cancer	0.00241	0.00375	CcSEcCtD
Icosapent ethyl—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00238	0.00371	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.00234	0.00676	CbGpPWpGaD
Icosapent ethyl—Gastritis—Epirubicin—liver cancer	0.00234	0.00365	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—ALDOB—liver cancer	0.00233	0.00674	CbGpPWpGaD
Icosapent ethyl—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00233	0.00363	CcSEcCtD
Icosapent ethyl—Cardiac arrest—Doxorubicin—liver cancer	0.00232	0.00362	CcSEcCtD
Icosapent ethyl—Dizziness—Sorafenib—liver cancer	0.00232	0.00362	CcSEcCtD
Icosapent ethyl—Mood swings—Doxorubicin—liver cancer	0.00232	0.00361	CcSEcCtD
Icosapent ethyl—Abdominal distension—Epirubicin—liver cancer	0.0023	0.00358	CcSEcCtD
Icosapent ethyl—Influenza—Epirubicin—liver cancer	0.00228	0.00356	CcSEcCtD
Icosapent ethyl—Asthma—Epirubicin—liver cancer	0.00228	0.00356	CcSEcCtD
Icosapent ethyl—Dysphagia—Epirubicin—liver cancer	0.00228	0.00356	CcSEcCtD
Icosapent ethyl—Pancreatitis—Epirubicin—liver cancer	0.00224	0.00349	CcSEcCtD
Icosapent ethyl—Vomiting—Sorafenib—liver cancer	0.00223	0.00348	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—CRABP1—liver cancer	0.00223	0.00643	CbGpPWpGaD
Icosapent ethyl—Angina pectoris—Epirubicin—liver cancer	0.00222	0.00347	CcSEcCtD
Icosapent ethyl—Rash—Sorafenib—liver cancer	0.00222	0.00345	CcSEcCtD
Icosapent ethyl—Dermatitis—Sorafenib—liver cancer	0.00221	0.00345	CcSEcCtD
Icosapent ethyl—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.0022	0.00343	CcSEcCtD
Icosapent ethyl—Bronchitis—Epirubicin—liver cancer	0.0022	0.00342	CcSEcCtD
Icosapent ethyl—Gastritis—Doxorubicin—liver cancer	0.00216	0.00337	CcSEcCtD
Icosapent ethyl—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00216	0.00336	CcSEcCtD
Icosapent ethyl—Abdominal distension—Doxorubicin—liver cancer	0.00213	0.00332	CcSEcCtD
Icosapent ethyl—Dysphagia—Doxorubicin—liver cancer	0.00211	0.00329	CcSEcCtD
Icosapent ethyl—Asthma—Doxorubicin—liver cancer	0.00211	0.00329	CcSEcCtD
Icosapent ethyl—Influenza—Doxorubicin—liver cancer	0.00211	0.00329	CcSEcCtD
Icosapent ethyl—Pancreatitis—Doxorubicin—liver cancer	0.00207	0.00323	CcSEcCtD
Icosapent ethyl—Hyperglycaemia—Epirubicin—liver cancer	0.00206	0.00321	CcSEcCtD
Icosapent ethyl—Angina pectoris—Doxorubicin—liver cancer	0.00206	0.00321	CcSEcCtD
Icosapent ethyl—Pneumonia—Epirubicin—liver cancer	0.00205	0.00319	CcSEcCtD
Icosapent ethyl—Infestation—Epirubicin—liver cancer	0.00204	0.00317	CcSEcCtD
Icosapent ethyl—Infestation NOS—Epirubicin—liver cancer	0.00204	0.00317	CcSEcCtD
Icosapent ethyl—Bronchitis—Doxorubicin—liver cancer	0.00203	0.00317	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	0.00201	0.00579	CbGpPWpGaD
Icosapent ethyl—Sweating—Epirubicin—liver cancer	0.00195	0.00304	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—HPGDS—liver cancer	0.00195	0.00562	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	0.00194	0.00559	CbGpPWpGaD
Icosapent ethyl—Epistaxis—Epirubicin—liver cancer	0.00192	0.00299	CcSEcCtD
Icosapent ethyl—Sinusitis—Epirubicin—liver cancer	0.00191	0.00298	CcSEcCtD
Icosapent ethyl—Hyperglycaemia—Doxorubicin—liver cancer	0.00191	0.00297	CcSEcCtD
Icosapent ethyl—Pneumonia—Doxorubicin—liver cancer	0.00189	0.00295	CcSEcCtD
Icosapent ethyl—Infestation NOS—Doxorubicin—liver cancer	0.00188	0.00294	CcSEcCtD
Icosapent ethyl—Infestation—Doxorubicin—liver cancer	0.00188	0.00294	CcSEcCtD
Icosapent ethyl—Rhinitis—Epirubicin—liver cancer	0.00183	0.00286	CcSEcCtD
Icosapent ethyl—Pharyngitis—Epirubicin—liver cancer	0.00181	0.00283	CcSEcCtD
Icosapent ethyl—Sweating—Doxorubicin—liver cancer	0.00181	0.00282	CcSEcCtD
Icosapent ethyl—Epistaxis—Doxorubicin—liver cancer	0.00178	0.00277	CcSEcCtD
Icosapent ethyl—Sinusitis—Doxorubicin—liver cancer	0.00177	0.00276	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	0.00176	0.00509	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—ALB—liver cancer	0.00174	0.00502	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism—PSMD10—liver cancer	0.00174	0.00501	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism—PSMA4—liver cancer	0.00174	0.00501	CbGpPWpGaD
Icosapent ethyl—Rhinitis—Doxorubicin—liver cancer	0.0017	0.00264	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—GOT2—liver cancer	0.00169	0.00487	CbGpPWpGaD
Icosapent ethyl—Pharyngitis—Doxorubicin—liver cancer	0.00168	0.00262	CcSEcCtD
Icosapent ethyl—Chills—Epirubicin—liver cancer	0.00164	0.00256	CcSEcCtD
Icosapent ethyl—Arrhythmia—Epirubicin—liver cancer	0.00163	0.00255	CcSEcCtD
Icosapent ethyl—Alopecia—Epirubicin—liver cancer	0.00162	0.00252	CcSEcCtD
Icosapent ethyl—Malnutrition—Epirubicin—liver cancer	0.00159	0.00248	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—CYP2E1—liver cancer	0.00159	0.00458	CbGpPWpGaD
Icosapent ethyl—Dysgeusia—Epirubicin—liver cancer	0.00156	0.00243	CcSEcCtD
Icosapent ethyl—Back pain—Epirubicin—liver cancer	0.00154	0.0024	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	0.00154	0.00443	CbGpPWpGaD
Icosapent ethyl—Chills—Doxorubicin—liver cancer	0.00152	0.00237	CcSEcCtD
Icosapent ethyl—Arrhythmia—Doxorubicin—liver cancer	0.00151	0.00236	CcSEcCtD
Icosapent ethyl—Alopecia—Doxorubicin—liver cancer	0.00149	0.00233	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—CYCS—liver cancer	0.00148	0.00429	CbGpPWpGaD
Icosapent ethyl—Ill-defined disorder—Epirubicin—liver cancer	0.00148	0.0023	CcSEcCtD
Icosapent ethyl—Malnutrition—Doxorubicin—liver cancer	0.00147	0.0023	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—GGT1—liver cancer	0.00146	0.00421	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism—GOT1—liver cancer	0.00146	0.00421	CbGpPWpGaD
Icosapent ethyl—Dysgeusia—Doxorubicin—liver cancer	0.00144	0.00225	CcSEcCtD
Icosapent ethyl—Malaise—Epirubicin—liver cancer	0.00143	0.00224	CcSEcCtD
Icosapent ethyl—Vertigo—Epirubicin—liver cancer	0.00143	0.00223	CcSEcCtD
Icosapent ethyl—Syncope—Epirubicin—liver cancer	0.00143	0.00222	CcSEcCtD
Icosapent ethyl—Back pain—Doxorubicin—liver cancer	0.00142	0.00222	CcSEcCtD
Icosapent ethyl—Loss of consciousness—Epirubicin—liver cancer	0.0014	0.00218	CcSEcCtD
Icosapent ethyl—Cough—Epirubicin—liver cancer	0.00139	0.00217	CcSEcCtD
Icosapent ethyl—Hypertension—Epirubicin—liver cancer	0.00137	0.00214	CcSEcCtD
Icosapent ethyl—Ill-defined disorder—Doxorubicin—liver cancer	0.00137	0.00213	CcSEcCtD
Icosapent ethyl—Myalgia—Epirubicin—liver cancer	0.00135	0.00211	CcSEcCtD
Icosapent ethyl—Arthralgia—Epirubicin—liver cancer	0.00135	0.00211	CcSEcCtD
Icosapent ethyl—Chest pain—Epirubicin—liver cancer	0.00135	0.00211	CcSEcCtD
Icosapent ethyl—Discomfort—Epirubicin—liver cancer	0.00134	0.00209	CcSEcCtD
Icosapent ethyl—Malaise—Doxorubicin—liver cancer	0.00133	0.00207	CcSEcCtD
Icosapent ethyl—Dry mouth—Epirubicin—liver cancer	0.00132	0.00207	CcSEcCtD
Icosapent ethyl—Vertigo—Doxorubicin—liver cancer	0.00132	0.00206	CcSEcCtD
Icosapent ethyl—Syncope—Doxorubicin—liver cancer	0.00132	0.00206	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—GSTP1—liver cancer	0.00131	0.00378	CbGpPWpGaD
Icosapent ethyl—Oedema—Epirubicin—liver cancer	0.0013	0.00202	CcSEcCtD
Icosapent ethyl—Anaphylactic shock—Epirubicin—liver cancer	0.0013	0.00202	CcSEcCtD
Icosapent ethyl—Loss of consciousness—Doxorubicin—liver cancer	0.00129	0.00202	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—HMOX1—liver cancer	0.00129	0.00373	CbGpPWpGaD
Icosapent ethyl—Infection—Epirubicin—liver cancer	0.00129	0.00201	CcSEcCtD
Icosapent ethyl—Cough—Doxorubicin—liver cancer	0.00128	0.002	CcSEcCtD
Icosapent ethyl—Shock—Epirubicin—liver cancer	0.00128	0.00199	CcSEcCtD
Icosapent ethyl—Hypertension—Doxorubicin—liver cancer	0.00127	0.00198	CcSEcCtD
Icosapent ethyl—Tachycardia—Epirubicin—liver cancer	0.00127	0.00198	CcSEcCtD
Icosapent ethyl—Hyperhidrosis—Epirubicin—liver cancer	0.00126	0.00196	CcSEcCtD
Icosapent ethyl—Myalgia—Doxorubicin—liver cancer	0.00125	0.00195	CcSEcCtD
Icosapent ethyl—Chest pain—Doxorubicin—liver cancer	0.00125	0.00195	CcSEcCtD
Icosapent ethyl—Arthralgia—Doxorubicin—liver cancer	0.00125	0.00195	CcSEcCtD
Icosapent ethyl—Discomfort—Doxorubicin—liver cancer	0.00124	0.00193	CcSEcCtD
Icosapent ethyl—Anorexia—Epirubicin—liver cancer	0.00124	0.00193	CcSEcCtD
Icosapent ethyl—Dry mouth—Doxorubicin—liver cancer	0.00123	0.00191	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—GSTM1—liver cancer	0.0012	0.00347	CbGpPWpGaD
Icosapent ethyl—Oedema—Doxorubicin—liver cancer	0.0012	0.00187	CcSEcCtD
Icosapent ethyl—Anaphylactic shock—Doxorubicin—liver cancer	0.0012	0.00187	CcSEcCtD
Icosapent ethyl—Infection—Doxorubicin—liver cancer	0.00119	0.00186	CcSEcCtD
Icosapent ethyl—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00118	0.00184	CcSEcCtD
Icosapent ethyl—Shock—Doxorubicin—liver cancer	0.00118	0.00184	CcSEcCtD
Icosapent ethyl—Insomnia—Epirubicin—liver cancer	0.00117	0.00183	CcSEcCtD
Icosapent ethyl—Tachycardia—Doxorubicin—liver cancer	0.00117	0.00183	CcSEcCtD
Icosapent ethyl—Hyperhidrosis—Doxorubicin—liver cancer	0.00116	0.00181	CcSEcCtD
Icosapent ethyl—Dyspnoea—Epirubicin—liver cancer	0.00116	0.00181	CcSEcCtD
Icosapent ethyl—Anorexia—Doxorubicin—liver cancer	0.00115	0.00179	CcSEcCtD
Icosapent ethyl—Dyspepsia—Epirubicin—liver cancer	0.00114	0.00178	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—CYP1A1—liver cancer	0.00114	0.00329	CbGpPWpGaD
Icosapent ethyl—Decreased appetite—Epirubicin—liver cancer	0.00113	0.00176	CcSEcCtD
Icosapent ethyl—Gastrointestinal disorder—Epirubicin—liver cancer	0.00112	0.00175	CcSEcCtD
Icosapent ethyl—Pain—Epirubicin—liver cancer	0.00111	0.00173	CcSEcCtD
Icosapent ethyl—Constipation—Epirubicin—liver cancer	0.00111	0.00173	CcSEcCtD
Icosapent ethyl—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00109	0.00171	CcSEcCtD
Icosapent ethyl—Insomnia—Doxorubicin—liver cancer	0.00109	0.00169	CcSEcCtD
Icosapent ethyl—Dyspnoea—Doxorubicin—liver cancer	0.00107	0.00167	CcSEcCtD
Icosapent ethyl—Feeling abnormal—Epirubicin—liver cancer	0.00107	0.00167	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—MTHFR—liver cancer	0.00106	0.00307	CbGpPWpGaD
Icosapent ethyl—Dyspepsia—Doxorubicin—liver cancer	0.00106	0.00165	CcSEcCtD
Icosapent ethyl—Decreased appetite—Doxorubicin—liver cancer	0.00104	0.00163	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—PPARA—liver cancer	0.00104	0.00301	CbGpPWpGaD
Icosapent ethyl—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00104	0.00162	CcSEcCtD
Icosapent ethyl—Pain—Doxorubicin—liver cancer	0.00103	0.0016	CcSEcCtD
Icosapent ethyl—Constipation—Doxorubicin—liver cancer	0.00103	0.0016	CcSEcCtD
Icosapent ethyl—Body temperature increased—Epirubicin—liver cancer	0.00103	0.0016	CcSEcCtD
Icosapent ethyl—Feeling abnormal—Doxorubicin—liver cancer	0.00099	0.00154	CcSEcCtD
Icosapent ethyl—Body temperature increased—Doxorubicin—liver cancer	0.00095	0.00148	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	0.000937	0.0027	CbGpPWpGaD
Icosapent ethyl—Asthenia—Epirubicin—liver cancer	0.000932	0.00145	CcSEcCtD
Icosapent ethyl—Pruritus—Epirubicin—liver cancer	0.000919	0.00143	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—PIK3CG—liver cancer	0.000893	0.00258	CbGpPWpGaD
Icosapent ethyl—Asthenia—Doxorubicin—liver cancer	0.000862	0.00134	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—PPARG—liver cancer	0.000862	0.00249	CbGpPWpGaD
Icosapent ethyl—Dizziness—Epirubicin—liver cancer	0.000859	0.00134	CcSEcCtD
Icosapent ethyl—Pruritus—Doxorubicin—liver cancer	0.00085	0.00133	CcSEcCtD
Icosapent ethyl—Vomiting—Epirubicin—liver cancer	0.000826	0.00129	CcSEcCtD
Icosapent ethyl—Rash—Epirubicin—liver cancer	0.000819	0.00128	CcSEcCtD
Icosapent ethyl—Dermatitis—Epirubicin—liver cancer	0.000818	0.00128	CcSEcCtD
Icosapent ethyl—Dizziness—Doxorubicin—liver cancer	0.000795	0.00124	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—PIK3CD—liver cancer	0.000785	0.00227	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism—ALB—liver cancer	0.000775	0.00224	CbGpPWpGaD
Icosapent ethyl—Vomiting—Doxorubicin—liver cancer	0.000764	0.00119	CcSEcCtD
Icosapent ethyl—Rash—Doxorubicin—liver cancer	0.000758	0.00118	CcSEcCtD
Icosapent ethyl—Dermatitis—Doxorubicin—liver cancer	0.000757	0.00118	CcSEcCtD
Icosapent ethyl—DGAT1—Metabolism—PIK3CB—liver cancer	0.000684	0.00197	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism—PIK3CA—liver cancer	0.000417	0.0012	CbGpPWpGaD
Icosapent ethyl—DGAT1—Metabolism—AKT1—liver cancer	0.000341	0.000983	CbGpPWpGaD
